AstraZeneca’s EUR 135 Million Investment in France
On January 21st, 2019, AstraZeneca inaugurated the extension of the group’s industrial site in the city of Dunkirk in Northern France. The launch was attended by Secretary of State to…
One of the special features of INNOTHERA, lies in its dual competency: pharmaceutical products and medical textiles. These two areas of expertise complement each other in a harmonious way and work towards the same end, that of treating common daily pathologies, such as venous disease. INNOTHERA’s pharmaceutical laboratory activity enables the Group to apply scientific knowledge and strict pharmaceutical processes to the medical textiles sector, thereby giving it a major advantage over its competitors.
Thanks to its human touch, INNOTHERA can concentrate its efforts on meeting assignments promptly and on achieving an excellent response rate, which is absolutely needed for managing the diversity of profiles and cultures within the group.
Currently, the INNOTHERA Group’s production is 100 % French, with exports amounting to more than 65 % of total sales, and covering more than 100 countries.
This is the price of a disciplined organisation and industrial process perfectly mastered that Innothera products in its French factories more than 20 drugs, controls 15 different dosage forms and distributes medicines in more than 100 countries.
Contact
Web: innothera.fr/en/
On January 21st, 2019, AstraZeneca inaugurated the extension of the group’s industrial site in the city of Dunkirk in Northern France. The launch was attended by Secretary of State to…
Franck Puget, managing director for CSL Behring in France, discusses the blood plasma specialist’s commitment to France, building bridges with public authorities, and regulatory attitudes towards rare disease treatments. …
Guillaume El Glaoui, co-founder and CEO of Laboratoires Majorelle, discusses what spurred the creation of the company, its success of gaining the first reimbursement ever of a condom in France,…
Eric Goupil, CEO of Unither Pharmaceuticals, discusses the company’s development strategy moving forward after the completion of a leveraged buyout in 2017. Additionally, Goupil shares the CDMO’s innovation capabilities as…
Mathilde Lignot-Leloup, director of the French Social Security, provides a fascinating look into the French social system and speaks about its ongoing transformation. She elaborates on change management processes within…
Thierry Hulot, president biopharma of Merck France, explains how France has become more open to diversity, while still needing significant reforms in the healthcare sector to remain competitive. He also…
Pascal Joly, general manager of Medac France, explains how he and his executive team have built the French affiliate from scratch, while highlighting the importance of gaining swift market access…
Guy Maugis, president of the Franco-German Chamber of Commerce and Industry, explains the impact of the Macron government on the attractiveness of France as well as the importance of a…
Philippe Truelle, President of CDM Lavoisier, highlights the financial impact of the EU’s Falsified Medicines Directive (FMD) on SMEs across Europe and explains how France is becoming increasingly attractive to…
Frédéric Collet, president Novartis France and general manager oncology explains the rationale behind Novartis’s consistent investment in France, the current shift in the company’s corporate culture and the main challenges inherent to…
In this exclusive interview, David Loew, executive vice president of Sanofi Pasteur, discusses the future of vaccines in France and the rest of the world, their strategic role in reducing…
Nicolas Bardonnet of Promega France discusses the standout growth of the company on the occasion of its 40th anniversary, collaboration with France’s biotech clusters and the growth drivers of the…
See our Cookie Privacy Policy Here
